Aldéric Fraslin

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 214 citations

Gortec 2014-01 Tpextreme, Neoadjuvant Therapy, Medicine +11

Impact of COVID-19 on healthcare organisation and cancer outcomes

A. Bardet, Aldéric Fraslin, J. Marghadi et al. · European Journal of Cancer · 2021 · 183 citations · Full text

A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial

Axel Le Cesne, Jean‐Yves Blay, Didier Cupissol et al. · Annals of Oncology · 2021 · 46 citations · Full text

Medicine, Surgery, Surgical Oncology +1

Cetuximab, Docetaxel and Cisplatin as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results of the GORTEC 2014-01 TPExtreme Randomized Trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · SSRN Electronic Journal · 2020 · 12 citations · Full text

Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life

Thierry Lebrét, Julia Bonastre, Aldéric Fraslin et al. · BMJ Open · 2023 · 10 citations · Full text